

Recent patent applications in antiviral vaccines

Patent #	Subject	Assignee(s)	Inventor(s)	Priority application date	Publication date
WO 200589792	A new recombinant protein comprising polypeptides bearing epitopes of human papilloma virus (HPV) antigens; useful for treating or preventing HPV infection, or for immunotherapy against the onset of malignant transformation due to HPV infection.	BT Pharma (Labège-Innopole, France); INSERM (France); Institut Pasteur (Paris); CNRS (France)	la Dant D, le Clerc C, Preville X, Timmerman B	3/18/2004	9/29/2005
WO 200587813	A new composition that comprises contacting an antigen-presenting cell with a chimeric antigen comprising an immune response domain and a target binding domain, which comprises a xenotypic antibody fragment; useful for eliciting a T-cell response against hepatitis B virus and hepatitis C virus infections.	ViRexx (Edmonton, Alberta, Canada)	George R, Noujaim A, Tyrrell L, Wang D	2/24/2004	9/22/2005
WO 200587799	A new isolated polypeptide that binds specifically to an oligosaccharide; useful in preparing a vaccine for treating or preventing HIV infection.	US Dept. of Health & Human Services (Washington, DC, USA)	Bewley CA	3/9/2004	9/22/2005
US 20050202045	A method for making a recombinant avian herpesvirus, comprising cotransfecting overlapping subgenomic fragments employing the subgenomic clones and enzymes; useful in producing therapeutic or prophylactic vaccines.	Schering-Plough Veterinary Corp. (Kenilworth, NJ, USA)	Cochran MD, Cook SM, Wild MA	6/14/2001	9/15/2005
WO 200585445	A novel recombinant varicella herpes-zoster virus comprising a bacterial artificial chromosome vector sequence; useful as a vaccine for treating varicella herpes-zoster virus infection.	Osaka University (Osaka, Japan)	Gomi Y, Mori Y, Nagaïke K, Takahashi M, Yamaishi K	3/5/2004	9/15/2005
EP 1574517	A novel recombinant or synthetic hepatitis C virus E1 envelope protein or its portion comprising one or more disulfide bonds between a specific pair of cysteines; useful as vaccine for hepatitis C virus.	Innogenetics (Ghent, Belgium)	Bosman A, Depla E, Depraetere S, Verheyden G	3/9/2004	9/14/2005
WO 200581716	A novel nucleic acid encoding chimeric polypeptides such as calreticulin and antigenic peptide from severe acute respiratory syndrome (SARS) coronavirus; useful as a DNA vaccine for SARS coronavirus.	Johns Hopkins University (Baltimore, MD, USA)	Hung C, Kim TW, Wu T	11/24/2003	9/9/2005
CN 1616654	A method for inactivating and purifying SARS virus; useful for preparing vaccines to combat SARS.	Kexing Biological Products (Shenzhen, China)	Han Z, Zhang J, Zhang Z	11/12/2003	5/18/2005
CN 1616491	A new fusion protein useful as a vaccine for treating and preventing influenza.	Qinghua University (Beijing)	Chen Y, Liu W	9/29/2004	5/18/2005
CN 1614011	A totally enclosed double-circulating column chromatography process for purifying inactivated virus vaccines.	Jiahe Biotechnology (Guangzhou, China)	He C, Le W	11/6/2003	5/11/2005
CN 1613503	A technique for preparing a virus vaccine using a bioreactor featuring a disk carrier for increasing the surface area used to grow cells, and a better culture condition created for increasing the culture density.	Jiahe Biotechnology (Guangzhou, China)	He C, Zhang J	11/6/2003	5/11/2005
IN 200200194	Liposomes containing novel peptide antigens; useful for regulating the immune response and for the development of therapeutic agents for the prevention and treatment of hepatitis B virus-associated diseases.	Mogam Biotechnology Research Institute (Yongin, South Korea)	Chang JS, Cheong H, Cho SY, Choi MJ, Hwang Y, Kim TY, Lee KU	4/3/2002	3/11/2005

Source: Thomson Scientific Search Service (formerly Derwent). The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1725 Duke Street, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) DERWENT (<http://www.thomson.com/scientific>).

